{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:45:23Z","timestamp":1787240723444,"version":"build-2736575974"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.phrs.2022.106628","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T11:41:40Z","timestamp":1671622900000},"page":"106628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer"],"prefix":"10.1016","volume":"187","author":[{"given":"Alejandra","family":"Estepa-Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Garc\u00eda-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"L\u00e9rida-Viso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Blandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Galiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Sancenon-Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Orz\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"Mart\u00ednez-M\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106628_bib1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the national cancer institute\u2019s surveillance, epidemiology, and end results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2022.106628_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.addr.2021.03.018","article-title":"The past, present, and future of breast cancer models for nanomedicine development","volume":"173","author":"Boix-Montesinos","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2022.106628_bib3","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Disco"},{"key":"10.1016\/j.phrs.2022.106628_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jconrel.2020.04.045","article-title":"Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic","volume":"323","author":"Galiana","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2022.106628_bib7","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1878-0261.12761","article-title":"Clearance of therapy-induced senescent tumor cells by the senolytic ABT-263 via interference with BCL-XL\u2013BAX interaction","volume":"14","author":"Saleh","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib8","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809355","article-title":"A versatile drug delivery system targeting senescent cells","volume":"10","author":"Mu\u00f1oz\u2010Esp\u00edn","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2022.106628_bib9","first-page":"1","article-title":"Senolysis reduces senescence in veins and cancer cell migration","volume":"2100149","author":"Estepa-Fern\u00e1ndez","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2022.106628_bib10","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA Approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106628_bib11","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA Approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106628_bib12","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106628_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01597-x","article-title":"Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer","volume":"20","author":"Huang","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.phrs.2022.106628_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Disco"},{"key":"10.1016\/j.phrs.2022.106628_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fonc.2018.00164","article-title":"Non-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy","volume":"0","author":"Saleh","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/acel.12597","article-title":"DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age","volume":"16","author":"Kim","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2022.106628_bib17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm.4010","article-title":"Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice","volume":"22","author":"Chang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2022.106628_bib18","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-018-0543-y","article-title":"Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline","volume":"562","author":"Bussian","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106628_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/acel.12445","article-title":"Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors","volume":"15","author":"Zhu","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2022.106628_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms11190","article-title":"Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL","volume":"7","author":"Yosef","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106628_bib21","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2022.106628_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/bjh.12757","article-title":"The role of apoptosis in megakaryocytes and platelets","volume":"165","author":"Kile","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2022.106628_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acel.13142","article-title":"Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity","volume":"19","author":"Gonz\u00e1lez-Gualda","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2022.106628_bib24","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1021\/jacs.7b04985","article-title":"An OFF\u2013ON Two-Photon Fluorescent Probe for Tracking Cell Senescence in Vivo","volume":"139","author":"Lozano-Torres","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2022.106628_bib25","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1021\/acs.analchem.0c05447","article-title":"on Naphthalimide-Styrene Fluorophore for the in Vivo Tracking of Cellular Senescence","volume":"93","author":"Lozano-Torres","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.phrs.2022.106628_bib26","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 Inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.phrs.2022.106628_bib27","doi-asserted-by":"crossref","first-page":"16318","DOI":"10.1002\/chem.202001579","article-title":"Silica nanoparticles for navitoclax resistance overcoming in triple-negative breast cancer","volume":"26","author":"Vivo-Llorca","year":"2020","journal-title":"Chem. - A Eur. J."},{"key":"10.1016\/j.phrs.2022.106628_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5306\/wjco.v12.i3.164","article-title":"Overview of recent advances in metastatic triple negative breast cancer","volume":"12","author":"O\u2019Reilly","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib30","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib31","first-page":"1","article-title":"Exploiting senescence for the treatment of cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2022.106628_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ebiom.2019.01.056","article-title":"Senolytics and senostatics as adjuvant tumour therapy","volume":"41","author":"Short","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2022.106628_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jnci\/djab064","article-title":"Therapy-induced senescence: opportunities to improve anticancer therapy","volume":"113","author":"Prasanna","year":"2021","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"53","key":"10.1016\/j.phrs.2022.106628_bib34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s12276-021-00717-5","article-title":"Senescent tumor cells: an overlooked adversary in the battle against cancer","volume":"5312","author":"Park","year":"2021","journal-title":"Exp. Mol. Med"},{"key":"10.1016\/j.phrs.2022.106628_bib35","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cancers13030484","article-title":"Cancer response to therapy-induced senescence: a matter of dose and timing","volume":"Vol. 13","author":"Mongiardi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106628_bib36","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","article-title":"Senescent cells in cancer therapy: friends or foes","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.phrs.2022.106628_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082134","article-title":"Senescence and cancer: a review of clinical implications of senescence and senotherapies","volume":"12","author":"Wyld","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2022.106628_bib38","first-page":"3761","article-title":"A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib39","first-page":"1876","article-title":"DNA damage is able to induce senescence in tumor cells in vitro and in vivo","volume":"62","author":"te Poele","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib40","first-page":"5019","article-title":"Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells","volume":"58","author":"Wang","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib41","first-page":"1957","article-title":"p53 effects both the duration of G2\/M arrest and the fate of temozolomide-treated human glioblastoma cells","volume":"61","author":"Hirose","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib42","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Torres-Guzm\u00e1n","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106628_bib43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bcp.2018.01.050","article-title":"Ribociclib, a Cdk4\/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All","volume":"153","author":"Bortolozzi","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106628_bib44","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-15-2931","article-title":"Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4\/6","volume":"76","author":"Yoshida","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.yexcr.2017.09.031","article-title":"Palbociclib-induced autophagy and senescence in gastric cancer cells","volume":"360","author":"Valenzuela","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2022.106628_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbcan.2015.10.001","article-title":"Senescence and cancer: an evolving inflammatory paradox","volume":"1865","author":"Ruhland","year":"2016","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"10.1016\/j.phrs.2022.106628_bib47","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106628_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.phrs.2022.106628_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","article-title":"Distinct functions of senescence-associated immune responses in liver tumor surveillance and tumor progression","volume":"30","author":"Eggert","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2022.106628_bib50","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/0008-5472.CAN-04-1270","article-title":"Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers","volume":"65","author":"Roberson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.590813","article-title":"Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4\/6 Inhibitor Palbociclib","volume":"10","author":"Yu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020346","article-title":"Beyond tumor suppression: senescence in cancer stemness and tumor dormancy","volume":"9","author":"Triana-Mart\u00ednez","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106628_bib53","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bcp.2018.12.013","article-title":"Tumor cell escape from therapy-induced senescence","volume":"162","author":"Saleh","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106628_bib54","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1158\/0008-5472.CAN-18-3437","article-title":"Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy","volume":"79","author":"Saleh","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41570-019-0108-0","article-title":"The chemistry of senescence","volume":"3","author":"Lozano-Torres","year":"2019","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.phrs.2022.106628_bib56","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2022.106628_bib57","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2022.106628_bib58","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib59","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Shoemaker","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2022.106628_bib60","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1535-7163.MCT-11-0415","article-title":"The Bcl-2\/Bcl-X L\/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo","volume":"10","author":"Chen","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2022.106628_bib61","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1038\/s41418-020-0564-6","article-title":"BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer","volume":"27","author":"Shahbandi","year":"2020","journal-title":"Cell Death Differ."},{"issue":"10","key":"10.1016\/j.phrs.2022.106628_bib62","first-page":"1","article-title":"Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence","volume":"101","author":"Fleury","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106628_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201810234","article-title":"Targeting senescent cells in translational medicine","volume":"11","author":"Paez\u2010Ribes","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.phrs.2022.106628_bib64","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1021\/jm049354h","article-title":"Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4\/6","volume":"48","author":"Toogood","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106628_bib65","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.phrs.2022.106628_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-019-0327-5","article-title":"Therapeutic effect of palbociclib in chondrosarcoma: Implication of cyclin-dependent kinase 4 as a potential target","volume":"17","author":"Ouyang","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phrs.2022.106628_bib67","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: A review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106628_bib68","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.01.007","article-title":"Proliferative suppression by CDK4\/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells","volume":"138","author":"Rivadeneira","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2022.106628_bib69","first-page":"1","article-title":"Intraoperative identification of liver cancer microfoci using a targeted near-infrared fluorescent probe for imaging-guided surgery","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2022.106628_bib70","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, erbb2-negative advanced breast cancer: a randomized clinical trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib71","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2022.106628_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0189007","article-title":"Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106628_bib73","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1158\/1541-7786.MCR-19-1181","article-title":"Aberrant induction of a mesenchymal\/stem cell program engages senescence in normal mammary epithelial cells","volume":"19","author":"Bryson","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2022.106628_bib74","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.3389\/fonc.2021.740002","article-title":"Palbociclib induces senescence in melanoma and breast cancer cells and leads to additive growth arrest in combination with irradiation","volume":"11","author":"Jost","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2022.106628_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091353","article-title":"Combination therapy of navitoclax with chemotherapeutic agents in solid tumors and blood cancer: a review of current evidence","volume":"13","author":"Nor Hisam","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2022.106628_bib76","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00280-014-2530-9","article-title":"Mechanism-based pharmacokinetic\/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia","volume":"74","author":"Kaefer","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106628_bib77","article-title":"Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity","volume":"11","author":"He","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2022.106628_bib78","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1002\/anie.201204663","article-title":"Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles","volume":"51","author":"Agostini","year":"2012","journal-title":"Angew. Chem. - Int. Ed."},{"key":"10.1016\/j.phrs.2022.106628_bib79","doi-asserted-by":"crossref","first-page":"15152","DOI":"10.1002\/anie.202004142","article-title":"Real-time in vivo detection of cellular senescence through the controlled release of the NIR fluorescent dye Nile Blue","volume":"59","author":"Lozano-Torres","year":"2020","journal-title":"Angew. Chem. - Int. Ed."},{"key":"10.1016\/j.phrs.2022.106628_bib80","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13133","article-title":"Galactose-modified duocarmycin prodrugs as senolytics","volume":"19","author":"Guerrero","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2022.106628_bib81","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41422-020-0314-9","article-title":"Elimination of senescent cells by \u03b2-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:45:22Z","timestamp":1760913922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822005746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":81,"alternative-id":["S1043661822005746"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106628","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106628"}}